CN101795682A - 直接起效和可逆的p2y12抑制剂的静脉内和口服给药 - Google Patents

直接起效和可逆的p2y12抑制剂的静脉内和口服给药 Download PDF

Info

Publication number
CN101795682A
CN101795682A CN200880023071A CN200880023071A CN101795682A CN 101795682 A CN101795682 A CN 101795682A CN 200880023071 A CN200880023071 A CN 200880023071A CN 200880023071 A CN200880023071 A CN 200880023071A CN 101795682 A CN101795682 A CN 101795682A
Authority
CN
China
Prior art keywords
described method
chemical compound
unit dose
compound
adp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN200880023071A
Other languages
English (en)
Chinese (zh)
Inventor
R·M·斯卡伯勒
D·D·格雷特莱
P·B·康利
P·安德烈
A·赫查勒拉哈
D·R·菲利普斯
A·潘德尔
W·黄
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Portola Pharmaceuticals LLC
Original Assignee
Portola Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Portola Pharmaceuticals LLC filed Critical Portola Pharmaceuticals LLC
Publication of CN101795682A publication Critical patent/CN101795682A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN200880023071A 2007-05-02 2008-05-02 直接起效和可逆的p2y12抑制剂的静脉内和口服给药 Pending CN101795682A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US91564907P 2007-05-02 2007-05-02
US60/915,649 2007-05-02
US94792107P 2007-07-03 2007-07-03
US60/947,921 2007-07-03
PCT/US2008/062518 WO2008137753A2 (en) 2007-05-02 2008-05-02 Intravenous and oral dosing of a direct-acting and reversible p2y12 inhibitor

Publications (1)

Publication Number Publication Date
CN101795682A true CN101795682A (zh) 2010-08-04

Family

ID=39587015

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200880023071A Pending CN101795682A (zh) 2007-05-02 2008-05-02 直接起效和可逆的p2y12抑制剂的静脉内和口服给药

Country Status (17)

Country Link
US (2) US20090048216A1 (cg-RX-API-DMAC7.html)
EP (1) EP2079464A2 (cg-RX-API-DMAC7.html)
JP (1) JP2010526101A (cg-RX-API-DMAC7.html)
KR (1) KR20100029746A (cg-RX-API-DMAC7.html)
CN (1) CN101795682A (cg-RX-API-DMAC7.html)
AU (1) AU2008247483A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0811476A2 (cg-RX-API-DMAC7.html)
CA (1) CA2686203A1 (cg-RX-API-DMAC7.html)
CO (1) CO6241104A2 (cg-RX-API-DMAC7.html)
EA (1) EA200901473A1 (cg-RX-API-DMAC7.html)
EC (1) ECSP099778A (cg-RX-API-DMAC7.html)
GT (1) GT200900284A (cg-RX-API-DMAC7.html)
IL (1) IL201834A0 (cg-RX-API-DMAC7.html)
MA (1) MA31663B1 (cg-RX-API-DMAC7.html)
MX (1) MX2009011843A (cg-RX-API-DMAC7.html)
TN (1) TN2009000451A1 (cg-RX-API-DMAC7.html)
WO (1) WO2008137753A2 (cg-RX-API-DMAC7.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA017402B1 (ru) * 2005-11-03 2012-12-28 Портола Фармасьютикалз, Инк. [4-(6-галоген-7-замещенные-2,4-диоксо-1,4-дигидро-2н-хиназолин-3-ил)фенил]-5-хлортиофен-2-илсульфонилмочевины, их формы, способы получения соединений, фармацевтические композиции, содержащие эти соединения, и их применение
BRPI0808422A2 (pt) * 2007-03-06 2015-06-23 Novartis Ag Compostos orgânicos bicíclicos adequados para o tratamento de condições inflamatórias ou alérgicas
CN101720324A (zh) * 2007-05-02 2010-06-02 波托拉医药品公司 [4-(6-氟-7-甲基氨基-2,4-二氧代-1,4-二氢-2h-喹唑啉-3-基)-苯基]-5-氯-噻吩-2-基-磺酰基脲盐、其相关的形式和方法
US20090156620A1 (en) * 2007-05-02 2009-06-18 Portola Pharmaceuticals, Inc. [4-(6-fluoro-7-methylamino-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylurea salts, forms and methods related thereto
US9427448B2 (en) * 2009-11-11 2016-08-30 The Medicines Company Methods of treating, reducing the incidence of, and/or preventing ischemic events
CN106075455A (zh) * 2008-12-30 2016-11-09 丹麦国家医院 鉴定发展成器官功能衰竭的风险提高的危重患者的方法及用于其治疗的化合物
US10376532B2 (en) 2009-11-11 2019-08-13 Chiesi Farmaceutici, S.P.A. Methods of treating, reducing the incidence of, and/or preventing ischemic events
DK2498731T3 (da) 2009-11-11 2020-03-02 Chiesi Farm Spa Fremgangsmåder til behandling eller forebyggelse af stenttrombose
CA2785487C (en) * 2009-12-23 2017-11-28 Ratiopharm Gmbh Solid pharmaceutical dosage form of ticagrelor
US20130165459A1 (en) 2010-01-12 2013-06-27 Norvartis Pharma Ag Pharmaceutical composition and dosage forms of elinogrel and methods of use thereof
WO2011137459A1 (en) * 2010-04-30 2011-11-03 Portola Pharmaceuticals, Inc. Dosage forms of elinogrel and methods of injectable administration thereof
WO2012072743A1 (en) * 2010-12-01 2012-06-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Method and kits for determining platelet susceptibility to activation in a patient
US8987285B2 (en) * 2010-12-03 2015-03-24 Portola Pharmaceuticals, Inc. Pharmaceutical compositions, dosage forms and new forms of the compound of formula (I), and methods of use thereof
MX393334B (es) 2017-03-15 2025-03-24 Idorsia Pharmaceuticals Ltd Administración subcutánea de un antagonista del receptor p2y12.
MA49452A (fr) 2017-06-23 2021-05-05 Chiesi Farm Spa Procédé de prévention de thrombose de shunt de l'artère systémique-pulmonaire
CN107462648B (zh) * 2017-08-21 2019-09-27 盐城锦明药业有限公司 一种Cangrelor中间体腺苷-2-硫酮的高效液相色谱检测方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6906063B2 (en) 2000-02-04 2005-06-14 Portola Pharmaceuticals, Inc. Platelet ADP receptor inhibitors
EA017402B1 (ru) 2005-11-03 2012-12-28 Портола Фармасьютикалз, Инк. [4-(6-галоген-7-замещенные-2,4-диоксо-1,4-дигидро-2н-хиназолин-3-ил)фенил]-5-хлортиофен-2-илсульфонилмочевины, их формы, способы получения соединений, фармацевтические композиции, содержащие эти соединения, и их применение

Also Published As

Publication number Publication date
EP2079464A2 (en) 2009-07-22
IL201834A0 (en) 2010-06-16
KR20100029746A (ko) 2010-03-17
GT200900284A (es) 2012-01-31
CA2686203A1 (en) 2008-11-13
ECSP099778A (es) 2010-01-29
EA200901473A1 (ru) 2010-06-30
CO6241104A2 (es) 2011-01-20
BRPI0811476A2 (pt) 2014-11-04
US20090048216A1 (en) 2009-02-19
TN2009000451A1 (en) 2011-03-31
JP2010526101A (ja) 2010-07-29
WO2008137753A2 (en) 2008-11-13
AU2008247483A1 (en) 2008-11-13
MX2009011843A (es) 2010-04-22
WO2008137753A3 (en) 2009-02-12
MA31663B1 (fr) 2010-09-01
US20120009172A1 (en) 2012-01-12

Similar Documents

Publication Publication Date Title
CN101795682A (zh) 直接起效和可逆的p2y12抑制剂的静脉内和口服给药
US8058284B2 (en) [4-(6-halo-7-substituted-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylureas and forms and methods related thereto
JP6820282B2 (ja) スルホンアミド誘導体及びそれを含有する医薬組成物
TW201731824A (zh) α４β７整合蛋白抑制劑
US20090042916A1 (en) [4-(6-fluoro-7-methylamino-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylurea salts, forms and methods related thereto
US20120129876A1 (en) [4-(6-fluoro-7-methylamino-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylurea salts, forms and methods related thereto
HK1121051B (en) [4-(6-halo-7-substituted-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylureas and forms and methods related thereto
KR20070107156A (ko) 공지된 피롤리딘 Ｘａ 인자 억제제의 결정질 형태

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20100804